Sistemas de expresión para proteínas terapéuticas recombinantes Expression Systems for Therapeutic Recombinant Proteins

Several biopharmaceutical products based on recombinant proteins are manufactured at present by biopharma- ceutical industry. Expression systems to obtain biopharmaceuticals are based on cloning vectors of genes coding for the protein of interest into a suitable host cell such as bacteria, yeast and cellular lines derived from mammals. Several biopharmaceuticals such as clotting factors, hormones, cytokines and enzymes have been approved for their commercial distribution. Growing demand of medicines intended for the treatment of infectious and chronic diseases is impelling the development of new bio- technologies focused on the ecological production of harmless, efficient and fair cost biopharmaceuticals. By the relevance of biopharmaceutical products to biopharmaceutical industry, the aim of this work was to review the expression systems currently applied for the production of therapeutic recombinant proteins.

[1]  Gary Walsh,et al.  Biopharmaceuticals: recent approvals and likely directions. , 2005, Trends in biotechnology.

[2]  T. Smart,et al.  HEK293 cell line: a vehicle for the expression of recombinant proteins. , 2005, Journal of pharmacological and toxicological methods.

[3]  C. Felten,et al.  Development of a PCR method for mycoplasma testing of Chinese hamster ovary cell cultures used in the manufacture of recombinant therapeutic proteins. , 2004, Biologicals : journal of the International Association of Biological Standardization.

[4]  F. Wurm.  Production of recombinant protein therapeutics in cultivated mammalian cells , 2004, Nature Biotechnology.

[5]  R. Werner,et al.  Economic aspects of commercial manufacture of biopharmaceuticals. , 2004, Journal of biotechnology.

[6]  G. Walsh.  Second-generation biopharmaceuticals. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[7]  F. Schmidt,et al.  Recombinant expression systems in the pharmaceutical industry , 2004, Applied Microbiology and Biotechnology.

[8]  A. Roda,et al.  Biotechnological applications of bioluminescence and chemiluminescence. , 2004, Trends in biotechnology.

[9]  Christine Robinson,et al.  Preclinical safety testing of biotechnology-derived pharmaceuticals , 2004, Molecular biotechnology.

[10]  K. Mosdell,et al.  Current and future considerations for the new classes of biologicals. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[11]  S. Pohl,et al.  Genetic engineering of recombinant glycoproteins and glycosylation pathway in mammalian host cells , 1999, Glycoconjugate Journal.

[12]  K. Kitajima,et al.  N-Glycosylation/deglycosylation as a mechanism for the post-translational modification/remodification of proteins , 1995, Glycoconjugate Journal.

[13]  K. Brown,et al.  Genetic Vaccines and Therapy , 2003 .

[14]  A. Rathore,et al.  Analysis for residual host cell proteins and DNA in process streams of a recombinant protein product expressed in Escherichia coli cells. , 2003, Journal of pharmaceutical and biomedical analysis.

[15]  P. Shamlou,et al.  Scaleable processes for the manufacture of therapeutic quantities of plasmid DNA , 2003, Biotechnology and applied biochemistry.

[16]  Zhong Liu,et al.  Development of a Chinese Hamster Ovary Cell Line for Recombinant Adenovirus‐Mediated Gene Expression , 2003, Biotechnology progress.

[17]  Gary Walsh,et al.  Pharmaceutical biotechnology products approved within the European Union. , 2003, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[18]  J. Davison.  Towards safer vectors for the field release of recombinant bacteria. , 2002, Environmental biosafety research.

[19]  F. Collart,et al.  High throughput methods for gene cloning and expression. , 2002, Protein expression and purification.

[20]  Per Jonasson,et al.  Genetic design for facilitated production and recovery of recombinant proteins in Escherichia coli , 2002, Biotechnology and applied biochemistry.

[21]  A. Lovatt,et al.  Applications of quantitative PCR in the biosafety and genetic stability assessment of biotechnology products , 2002, Reviews in Molecular Biotechnology.

[22]  J. Boonstra,et al.  Introduction of an N-Glycosylation Site Increases Secretion of Heterologous Proteins in Yeasts , 2000, Applied and Environmental Microbiology.

[23]  R. Nakamoto,et al.  Use of chemical chaperones in the yeast Saccharomyces cerevisiae to enhance heterologous membrane protein expression: high-yield expression and purification of human P-glycoprotein. , 2000, Archives of biochemistry and biophysics.

[24]  Michael J. Betenbaugh,et al.  Part I. Bcl-2 and Bcl-xL limit apoptosis upon infection with alphavirus vectors. , 2000 .

[25]  A. Hooker,et al.  Analysis of glycoprotein heterogeneity by capillary electrophoresis and mass spectrometry , 2000, Molecular biotechnology.

[26]  O Doblhoff-Dier,et al.  Quality control and assurance from the development to the production of biopharmaceuticals. , 1999, Trends in biotechnology.

[27]  James E. Bailey,et al.  Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity , 1999, Nature Biotechnology.

[28]  J. Raso,et al.  Biotech pharmaceuticals and biotherapy: an overview. , 1998, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[29]  G. Braus,et al.  Three classes of mammalian transcription activation domain stimulate transcription in Schizosaccharomyces pombe , 1997, The EMBO journal.

[30]  K. Haberer,et al.  Strategies to avoid virus transmissions by biopharmaceutic products. , 1997, Archives of virology. Supplementum.

[31]  R Thorpe,et al.  The use of bioassays for the characterisation and control of biological therapeutic products produced by biotechnology. , 1997, Developments in biological standardization.

[32]  D. I. Wang,et al.  Rapid monitoring of site-specific glycosylation microheterogeneity of recombinant human interferon-gamma. , 1996, Analytical chemistry.

[33]  D. James,et al.  Posttranslational processing of recombinant human interferon‐γ in animal expression systems , 1996, Protein science : a publication of the Protein Society.

[34]  Helen Kreuzer,et al.  Recombinant DNA and biotechnology : a guide for teachers , 1996 .

[35]  Ben Trijzelaar.  Regulatory affairs and biotechnology in Europe: III. Introduction into good regulatory practice — Validation of virus removal and inactivation , 1993, Biotherapy.

[36]  B. Takács,et al.  Preparation of clinical grade proteins produced by recombinant DNA technologies. , 1991, Journal of immunological methods.

[37]  Bendig Mm.  The production of foreign proteins in mammalian cells. , 1988 .

[38]  G. An,et al.  Expression vehicles used in recombinant DNA technology. , 1983, Biotechnology advances.